How High Blood Sugar Triggers a Protein That May Worsen Metabolic Disease

Adipsin is a protein produced by both fat and liver tissue. Scientists have known for years that adipsin affects how the body regulates metabolism and immunity, but they didn't fully understand how—or why—the liver produces more of it during metabolic disease.

A new study published in Molecular Medicine (September 2026) reveals that high blood sugar itself triggers the liver to make more adipsin protein. This is an important distinction: the genes encoding adipsin don't necessarily turn on; instead, the protein is assembled more rapidly from existing genetic instructions. This process, called translational regulation, was previously unknown in adipsin biology.

Researchers examined liver tissue from people with type 2 diabetes and compared it to tissue from non-diabetic individuals. They found that adipsin protein levels were significantly elevated in those with type 2 diabetes, and the amount correlated with glycated hemoglobin—a measure of average blood sugar control over time.

The team then tested this in animal models of both type 1 and type 2 diabetes, as well as in cultured liver cells. In every case, adipsin protein increased during periods of high blood sugar or glucose exposure. Importantly, this increase happened without a corresponding increase in the messenger RNA that codes for adipsin, pointing to translational regulation as the mechanism.

The researchers identified the molecular machinery behind this process. When glucose levels rise in liver cells, it activates a pathway involving the mammalian target of rapamycin (mTOR) and alters the phosphorylation state of a protein called eukaryotic initiation factor 2-alpha (eIF2α). These changes essentially speed up the assembly of adipsin protein from its genetic blueprint.

This is a finely tuned system: glucose directly controls how fast adipsin is made, without requiring changes to gene expression. The more glucose present, the more adipsin the liver produces.

The connection between adipsin and metabolic control suggests a potential feedback loop: when blood sugar rises, the body produces more adipsin, which itself influences glucose uptake and tolerance. If adipsin plays a role in worsening blood sugar control, then high blood sugar could create conditions that perpetuate the problem.

While this study provides important mechanistic insight, it's an early-stage discovery. Researchers have identified what happens and how, but the full clinical significance—especially for people with type 1 diabetes—remains to be determined. More research is needed to understand whether reducing adipsin production could improve blood sugar control, or whether adipsin is simply a marker of underlying metabolic dysfunction.

The study used hepatocyte-specific adipsin knockdown (reducing adipsin in liver cells) to explore metabolic function, laying groundwork for future investigations. Understanding how the body regulates adipsin in response to glucose could open new avenues for treating metabolic diseases, including both type 1 and type 2 diabetes.

For now, this research reinforces why blood sugar management matters at the molecular level—high glucose doesn't just affect your immediate health; it triggers cascading changes in how your body's proteins are made and function.

Source: Molecular medicine (Cambridge, Mass.). Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.